German Health Care Reform: Raising the Innovation Threshold
Executive Summary
New reference price groups will include both patented and off-patent substances within the same class. Proving true innovation will be the only way to command premium prices. That won't be easy.
You may also be interested in...
Pricing Experiments: Pharmas Get Creative in Germany
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
Pricing Experiments: Pharmas Get Creative in Germany
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
Pfizer Gets Closer to Customers
Pfizer's decision to bypass UK wholesalers and go direct to pharmacies should ultimately give it better control over product discounting. Other manufacturers are watching closely, and not just in the UK.